[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$63169m
The market is experiencing a sharp downturn, with significant social media buzz around potential regulatory scrutiny. Investors are closely watching for any official statements.
About $63169m
$63169m appears to be a digital asset or cryptocurrency.
Engagements: XX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
1-Year High: XXXXX on 2025-11-03
1-Year Low: XX on 2025-11-05
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-11-03
1-Year Low: X on 2025-11-03
| Social Network | X |
|---|---|
| Mentions | XX |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $63169m in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-11-03
1-Year Low: X on 2025-11-03
Top assets mentioned In the posts about $63169m in the last XX hours
Hims & Hers Health, Inc. (HIMS) Hims & Hers Health, Inc. (HIMS)
Top topics mentioned In the posts about $63169m in the last XX hours
hims hers, stocks consumer defensive, $hims, $59898m, $58024m, $605625m, $5565m, $novcde
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$HIMS Hims & Hers Health Q3 2025 Earnings Summary Q3 Results: EPS: $XXXX miss by $XXXX (vs. $XXXX consensus) Revenue: $598.98M up XXXX% YoY beat vs. $580.24M consensus Guidance: Q4 Revenue: $605625M (below $631.69M consensus) Q4 Adj. EBITDA: $5565M Strategic Update: Novo Nordisk Partnership Talks: Hims & Hers is in active discussions with Novo Nordisk to make Wegovy injections and oral Wegovy (pending FDA approval) available via its platform. The collaboration aims to expand consumer access to GLP-1 treatments under prescriber guidance. The company clarified that no definitive agreement has"
X Link @tenet_research 2025-11-03T21:12Z 452.2K followers, 1234 engagements